Worth reading
46Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-3904
¥ millionWording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationFiscal year ending March 20268 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥65,845 million-5.6%
Operating profit¥381 million-56.3%
Ordinary income¥356 million-30.8%
Net income¥-783 million
Selling, general and administrative expensesSG&A expenses were stated to have declined, but the amount and SG&A expenses-to-net-sales ratio were Not disclosed
Full-year earnings forecast
Net Sales
¥66,000 million
Operating profit
¥1,000 million
Ordinary income
¥900 million
Profit attributable to owners of the parent
¥600 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Decline in gross profit due to lower sales of key overseas products
- Reduction in SG&A expenses
- Equity in earnings of affiliates
- Recognition of foreign exchange losses
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
- US$1 = ¥150
- €1 = ¥175
- S$1 = ¥117
New initiatives
- Establishment of a production system to support increased output in response to a new add-on for the administration of anticancer drugs
- Launch of operations by JMS帝人ホームメディカルケア株式会社
- Conversion of JMS韓国 from a manufacturing base into a sales company
- Joint delivery of domestic medical-use products by 4 medical manufacturers
- Increased investment in new and growth areas ahead of the next medium-term management plan
Segment results
Japan
Net Sales
¥44,759 million-2.8%
Profit
¥949 million-36.0%
Singapore
Net Sales
¥23,726 million-10.6%
Profit
¥-47 million
China
Net Sales
¥3,985 million-4.3%
Profit
¥87 million
Philippines
Net Sales
¥3,335 million-8.9%
Profit
¥-727 million
Germany
Net Sales
¥3,956 million-11.5%
Profit
¥473 million+4.1%
Other
Net Sales
¥5,929 million+17.5%
Profit
¥24 million
Medium-term management plan targets
Operating profit
¥2,500 million
Target fiscal yearFiscal year ending March 2027
ROIC
3.5 % or higher
Target fiscal yearFiscal year ending March 2027
Financial targets
ROIC
Target value3.5% or higher
Market Size / Share
The company stated that it steadily expanded its market share, but the figure was Not disclosedAnnual Dividend
Annual
¥17 per share
Interim
¥8.5 per share
End of period
¥8.5 per share
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Net Sales | ¥65,845 million (YoY -5.6%) |
| Operating profit | ¥381 million (YoY -56.3%) |
| Ordinary income | ¥356 million (YoY -30.8%) |
| Net income | ¥-783 million |
| Selling, general and administrative expenses | SG&A expenses were stated to have declined, but the amount and SG&A expenses-to-net-sales ratio were Not disclosed |
| Full-year earnings forecast | Net Sales ¥66,000 million / Operating profit ¥1,000 million / Ordinary income ¥900 million / Profit attributable to owners of the parent ¥600 million |
| Segment results | Japan Net Sales ¥44,759 million (YoY -2.8%) / Profit ¥949 million (YoY -36.0%) / Singapore Net Sales ¥23,726 million (YoY -10.6%) / Profit ¥-47 million / China Net Sales ¥3,985 million (YoY -4.3%) / Profit ¥87 million / Philippines Net Sales ¥3,335 million (YoY -8.9%) / Profit ¥-727 million / Germany Net Sales ¥3,956 million (YoY -11.5%) / Profit ¥473 million (YoY +4.1%) / Other Net Sales ¥5,929 million (YoY +17.5%) / Profit ¥24 million |
| Breakdown of Factors Affecting the Change | Decline in gross profit due to lower sales of key overseas products, Reduction in SG&A expenses, Equity in earnings of affiliates, Recognition of foreign exchange losses |
| Assumptions Underlying the Business Outlook | US$1 = ¥150, €1 = ¥175, S$1 = ¥117 |
| Medium-term management plan targets | Operating profit ¥2,500 million / ROIC 3.5 % or higher |
| Financial targets | ROIC Target value 3.5% or higher / Actual value Not disclosed |
| Annual Dividend | Annual ¥17 per share / Interim ¥8.5 per share / End of period ¥8.5 per share |
| Market Size / Share | The company stated that it steadily expanded its market share, but the figure was Not disclosed |
| New initiatives | Establishment of a production system to support increased output in response to a new add-on for the administration of anticancer drugs, Launch of operations by JMS帝人ホームメディカルケア株式会社, Conversion of JMS韓国 from a manufacturing base into a sales company, Joint delivery of domestic medical-use products by 4 medical manufacturers, Increased investment in new and growth areas ahead of the next medium-term management plan |
Items this document does not state (15)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Overseas, the blood and cell business declined, and lower sales of key overseas products weighed on profit. The recognition of a business restructuring loss associated with the reorganization of production facilities in South Korea as an extraordinary loss also contributed to the net loss for the period.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.